Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Absci Corp. (ABSI)
:ABSI
Holding ABSI?
Track your performance easily
ABSI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.45 - $6.72
Previous CloseN/A
Volume51.94M
Average Volume (3M)4.89M
Market Cap
$311.26M
Enterprise Value$303.13M
Total Cash (Recent Filing)$13.09M
Total Debt (Recent Filing)$4.13M
Price to Earnings (P/E)―
Beta2.85
Next Earnings
Mar 19, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding114,855,760
10 Day Avg. Volume9,284,026
30 Day Avg. Volume4,892,058
Standard Deviation0.35
R-Squared0.08
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)78.08
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue72.05
Enterprise Value/Gross Profit53.01
Enterprise Value/Ebitda-3.63
Forecast
1Y Price Target
$7.83Price Target Upside179.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
AbSci News
Bulls Say, Bears Say
Bulls Say
Innovative Product DevelopmentAbsci's AI-driven platform can design antibodies to precisely target an epitope with optimized interface contacts to ensure high potency and affinity.
Promising Clinical PipelineABS-201 represents a significant opportunity due to high patient demand for androgenetic alopecia treatment.
Strategic CollaborationsAMD's selection of Absci as one of its first collaborators in AI-driven drug discovery validates Absci’s leadership in the field.
Bears Say
CompetitionThe intensifying battle in TL1A space left some investors nervous regarding ABS-101 prospects, pressuring the stock.
Financial PerformanceFor 3Q24, the company reported revenues of $1.7M, compared to the consensus estimate of $1.8M, and a net loss of $0.24 per share, compared to the consensus estimated net loss of $0.19 per share.
Research And DevelopmentQ3 OpEx of $31M was above expectations driven by higher R&D due to a jump in lab operations as the preclinical pipeline advances toward Ph1.
---
Ownership Overview
27.72% Insiders
20.49% Mutual Funds
0.02% Other Institutional Investors
35.70% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABSI FAQ
What was Absci Corp.’s price range in the past 12 months?
Absci Corp. lowest stock price was $2.45 and its highest was $6.72 in the past 12 months.
What is Absci Corp.’s market cap?
Absci Corp.’s market cap is $311.26M.
When is Absci Corp.’s upcoming earnings report date?
Absci Corp.’s upcoming earnings report date is Mar 19, 2025 which is in 60 days.
How were Absci Corp.’s earnings last quarter?
Absci Corp. released its earnings results on Nov 12, 2024. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.194 by -$0.046.
Is Absci Corp. overvalued?
According to Wall Street analysts Absci Corp.’s price is currently Undervalued.
Does Absci Corp. pay dividends?
Absci Corp. does not currently pay dividends.
What is Absci Corp.’s EPS estimate?
Absci Corp.’s EPS estimate is -0.22.
How many shares outstanding does Absci Corp. have?
Absci Corp. has 114,855,760 shares outstanding.
What happened to Absci Corp.’s price movement after its last earnings report?
Absci Corp. reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.194. Following the earnings report the stock price went down -14.953%.
Which hedge fund is a major shareholder of Absci Corp.?
Currently, no hedge funds are holding shares in ABSI
---
AbSci Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.83 (179.64% Upside)
$7.83 (179.64% Upside)
Blogger Sentiment
Bullish
ABSI Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.52%
12-Months-Change
Fundamentals
Return on Equity
-49.11%
Trailing 12-Months
Asset Growth
-0.47%
Trailing 12-Months
Company Description
Absci Corp.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
---
ABSI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, such as collaborations with AstraZeneca and Twist Bioscience, financial stability, and upcoming strategic events. However, it also noted increased R&D expenses, a delay in the ABS-301 program, and modest revenue figures. The positive elements slightly outweigh the negative aspects.Read More>---
ABSI Stock 12 Month Forecast
Average Price Target
$7.83
▲(179.64% Upside)
Technical Analysis
Denali Therapeutics
―
Recursion Pharmaceuticals
―
Schrodinger
―
Repare Therapeutics
―
Quantum-Si
―
Omega Therapeutics
―
Best Analysts Covering ABSI
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
+49.97%
reiterated a buy rating 2 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of +49.97% per trade.
---